They do plenty of investor conferences. They really didn't need it. We seem to have survived that Seeking Alpha article. Although they went into vivid detail on everything that could go wrong, they did also think that getting approval of the drug was very, very high. We really need some news on someone stepping in and doing a new Lupron drug, since the patents are expiring. Something needs to force Abbv's hand into going strong with Elagolix.
Indeed that Seeking article is actually really good news for NBIX. Altho it did point out all the negatives one positive point is greater than all the negatives combined. It did point out to excellent chance of getting approved. That alone my friends will put NBIX at $16. GLTA.